Cargando…

The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity

ICI-related hepatotoxicity (IRH) is becoming more and more common as immune checkpoint inhibitors (ICIs) have begun to be increasingly approved and used in combination with other anti-tumor drugs worldwide. Steroids are the first choice for the treatment of IRH, but the subsequent optimal treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xing, Hui, Wang, Yang, Qu, Bo, Wei, Qiang, Li, Cuihua, Pan, Chao, Li, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9842701/ https://www.ncbi.nlm.nih.gov/pubmed/36623392 http://dx.doi.org/10.1016/j.tranon.2023.101619

Ejemplares similares

Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known
por: Zheng, Caiyun, et al.
Publicado: (2023)

Steroid-Refractory Immune-Related Adverse Events Induced by Checkpoint Inhibitors
por: Tomsitz, Dirk, et al.
Publicado: (2023)

Infliximab for Steroid-Refractory Immune Checkpoint Inhibitor-Induced Acute Pancreatitis
por: Townsend, Matthew J., et al.
Publicado: (2023)

Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis
por: Li, Yanlin, et al.
Publicado: (2023)

Checkpoint Inhibitors and Hepatotoxicity
por: Malnick, Stephen D. H., et al.
Publicado: (2021)

Toward the establishment of guidelines for the treatment of steroid‐refractory immune‐related hepatotoxicity
por: Yoshio, Sachiyo
Publicado: (2023)

Calcineurin inhibitors in steroid and anti‐TNF‐alpha refractory immune checkpoint inhibitor colitis
por: Zhang, Eva, et al.
Publicado: (2021)

Immune checkpoint inhibitor-related hepatotoxicity: A review
por: Remash, Devika, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologists’ Perspectives
por: Farshidpour, Maham, et al.
Publicado: (2022)

Overlapping Hepatotoxicity and Colitis Associated with Immune Checkpoint Inhibitors
por: Malik, Alexander, et al.
Publicado: (2023)

Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
por: Personeni, Nicola, et al.
Publicado: (2021)

Hepatotoxicity in immune checkpoint inhibitors: A pharmacovigilance study from 2014–2021
por: Xu, Ze, et al.
Publicado: (2023)

A Case of Immune Checkpoint Inhibitor Refractory Colitis Treated with Mycophenolate and High-dose Steroids
por: Alcantar, Daniel, et al.
Publicado: (2019)

Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis
por: Gatti-Mays, Margaret, et al.
Publicado: (2021)

A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy
por: Guan, Shasha, et al.
Publicado: (2023)

Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events
por: Araujo, Daniel V., et al.
Publicado: (2021)

Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers
por: Kim, Bum Jun, et al.
Publicado: (2017)

Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury
por: Doherty, Gary Joseph, et al.
Publicado: (2017)

Pulse corticosteroid therapy in the treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis: Case report and review
por: Lai, Kuan-Chang, et al.
Publicado: (2022)

Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
por: Xiong, Wei, et al.
Publicado: (2021)

Case Report: Successful Treatment of Steroid-Refractory Immune Checkpoint Inhibitor-Related Pure Red Cell Aplasia With Cyclosporin
por: Gérard, Alexandre, et al.
Publicado: (2020)

Infliximab in the treatment of tislelizumab-induced steroid-refractory immune checkpoint inhibitor-related pneumonia: case report and literature review
por: Chen, Zhujun, et al.
Publicado: (2022)

Biologic Therapy for Refractory Immune Checkpoint Inhibitor Colitis
por: Alorfi, Nasser M, et al.
Publicado: (2022)

Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status
por: Chauhan, Aman, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives
por: Federico, Piera, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches
por: Batista-Duharte, Alexander, et al.
Publicado: (2022)

Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges
por: Gan, Lu, et al.
Publicado: (2022)

Immune checkpoint inhibitors in cervical cancer: Current status and research progress
por: Xie, Yunkai, et al.
Publicado: (2022)

Immune checkpoint inhibitors
por: Hui, Enfu
Publicado: (2019)

Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
por: Beattie, Jason, et al.
Publicado: (2021)

Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers
por: Eso, Yuji, et al.
Publicado: (2020)

The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review
por: Brahm, Cyrillo G., et al.
Publicado: (2020)

Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis
por: Doms, J., et al.
Publicado: (2020)

Checkpoint inhibitor-induced hepatotoxicity: Role of liver biopsy and management approach
por: Bessone, Fernando, et al.
Publicado: (2022)

Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review
por: Pan, Lei, et al.
Publicado: (2023)

Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer
por: Lim, Sung Won, et al.
Publicado: (2019)

Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer
por: Kang, Byung Woog, et al.
Publicado: (2020)

The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
por: Jia, Xiao-Hui, et al.
Publicado: (2020)

A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil
por: Jespersen, Mette Syberg, et al.
Publicado: (2021)

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis
por: Mooradian, Meghan J, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5b17a3tre76vqainauelivrd80